Shots: The EU approval is based on two head-to-head P-I study for PK biosimilarity & P-III evaluating efficacy and safety assessing Imraldi vs Humira (40mg/0.8 ml) in patients with moderate-to-severe RA P-III study results: ACR20 @24wks (72.5% vs 72.0%); with comparable efficacy, safety & immunogenicity. Humira’s biosimilar is approved and indicated in RA, juvenile idiopathic […]Read More
